Maximizing Outcomes, Minimizing Costs
Synergy Biologics
Synergy Biologics is a vertically integrated biotechnology company focused on the development of a safe, reliable, effective, and affordable suite of products designed to enable the physician to achieve the best possible outcomes for each patient. Through our ability to control each and every aspect of tissue transplant, from recovery and screening through processing and distribution, we are committed to providing the very best quality to our customers.
All tissue is recovered from pre-screened, healthy, living donors during cesarean childbirth. Donor selection, tissue recovery and processing protocols adhere to all tissue banking standards to ensure patient safety, and are in accordance with standards, regulations, statutes and/or directives of the U.S. Food and Drug Administration (FDA) and other licensing and/or the American Association of Tissue Banks (AATB).
Our Mission
Our goal is to provide greater access to high quality allografts by leveraging our vertically integrated tissue supply chain to provide more cost effective allograft products to our patients and clinicians.
Our Values
Ensuring access to safe, reliable, and affordable surgical and wound care therapy through our vertically integrated biotech company, meeting FDA and AATB standards.
Our Advantage
Through vertical integration, Synergy Biologics can supply the same quality allografts as the competition at 40% of the cost. That’s up to 60% savings for our customers.
Company Timeline
Synergy Biologics Evolution

Market leading birth tissue Supply Chain launched
2013

ISO 5 Manufacturing Facility established
2015

Synergy Biologics created, thus completing the final stage of vertical integration and supply chain competitive advantage for amniotic tissue allografts
2016

Synergy Biologics launches surgiGRAFT™ , their flagship product a single layer amniotic tissue allograft nationwide
2016-2018

2018-2020

Regulatory Education Program on HCTPs/361 amniotic tissue allografts implemented nationwide with hospital and purchasing partners
2021

2022

Amniotic Tissue Regulatory Alignment Initiative with additional partner GPOs scales to maximize commoditization and patient access
2024
Meet Synergy Biologics
Executive Team

David Hill
CEO

Montie Lewing
VP Clinical Sales

Emily Williams
Executive Director of Quality & Reimbursement
